Trial Profile

Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics
Acronyms COVIVAC-ID

Most Recent Events

25 Aug 2023 Results (n=90) assessing the serological response and the neutralizing activity after BNT162b2 primary and booster vaccination in MS patients published in the European Journal of Neurology
03 Feb 2023 Status changed from recruiting to completed.
15 Jun 2021 Planned End Date changed from 31 Dec 2022 to 31 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com